Policy & Regulation
Asgard Therapeutics appoints chief medical officer
15 April 2026 - Asgard Therapeutics, a Swedish biotech company focused on in vivo direct cell reprogramming for cancer immunotherapy, announced on Tuesday the appointment of Prof Dr Wolfram Brugger as...
Mestag Therapeutics to present targeted LTBR agonist MST-0312 at AACR Annual Meeting
15 April 2026 - Mestag Therapeutics, a UK-based biotech company using fibroblast immunology to develop treatments for patients with cancer and inflammatory disease, announced on Tuesday that it has be...
CrossBridge Bio to be acquired by Eli Lilly
14 April 2026 - CrossBridge Bio Inc, a pre-clinical biotechnology company developing next-generation dual-payload antibody-drug conjugates (ADCs), announced on Tuesday that it has entered into a defin...
Groupe Rocher partners with Dassault Systèmes to accelerate cosmetics innovation using virtual twin technology
14 April 2026 - French software developer Dassault Systèmes (Euronext Paris:DSY) and beauty and wellness company Groupe Rocher on Tuesday announced a collaboration to enhance research and devel...
hVIVO signs influenza human challenge trial agreement with Traws Pharma
14 April 2026 - hVIVO plc (AIM:HVO), a specialist in conducting human challenge trials, announced on Tuesday that it has signed a clinical trial agreement with Traws Pharma (NASDAQ:TRAW), a clinical-s...
IDEAYA Biosciences and Servier report positive results from Phase 2/3 trial of darovasertib/crizotinib combination
14 April 2026 - US precision medicine oncology company IDEAYA Biosciences Inc (NASDAQ:IDYA) and French pharmaceutical company Servier announced on Monday positive topline results from their Phase 2/3 ...